Arcus Biosciences advances casdatifan combinations, reports $775M cash at midyear 2026
Arcus added three new clinical collaborations for its HIF-2α inhibitor casdatifan and said cash runway extends to at least the second half of 2028.
SEC filing
Latest
2 stories